These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21603651)

  • 1. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.
    Vasan S; Hurley A; Schlesinger SJ; Hannaman D; Gardiner DF; Dugin DP; Boente-Carrera M; Vittorino R; Caskey M; Andersen J; Huang Y; Cox JH; Tarragona-Fiol T; Gill DK; Cheeseman H; Clark L; Dally L; Smith C; Schmidt C; Park HH; Kopycinski JT; Gilmour J; Fast P; Bernard R; Ho DD
    PLoS One; 2011; 6(5):e19252. PubMed ID: 21603651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation.
    Dolter KE; Evans CF; Ellefsen B; Song J; Boente-Carrera M; Vittorino R; Rosenberg TJ; Hannaman D; Vasan S
    Vaccine; 2011 Jan; 29(4):795-803. PubMed ID: 21094270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
    Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
    PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.
    Vasan S; Schlesinger SJ; Huang Y; Hurley A; Lombardo A; Chen Z; Than S; Adesanya P; Bunce C; Boaz M; Boyle R; Sayeed E; Clark L; Dugin D; Schmidt C; Song Y; Seamons L; Dally L; Ho M; Smith C; Markowitz M; Cox J; Gill DK; Gilmour J; Keefer MC; Fast P; Ho DD
    PLoS One; 2010 Jan; 5(1):e8617. PubMed ID: 20111582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Safety and Immunogenicity of GTU
    Haidari G; Day S; Wood M; Ridgers H; Cope AV; Fleck S; Yan C; Reijonen K; Hannaman D; Spentzou A; Hayes P; Vogt A; Combadiere B; Cook A; McCormack S; Shattock RJ
    Front Immunol; 2019; 10():2911. PubMed ID: 31921170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.
    Elizaga ML; Li SS; Kochar NK; Wilson GJ; Allen MA; Tieu HVN; Frank I; Sobieszczyk ME; Cohen KW; Sanchez B; Latham TE; Clarke DK; Egan MA; Eldridge JH; Hannaman D; Xu R; Ota-Setlik A; McElrath MJ; Hay CM;
    PLoS One; 2018; 13(9):e0202753. PubMed ID: 30235286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.
    Hannaman D; Dupuy LC; Ellefsen B; Schmaljohn CS
    Vaccine; 2016 Jun; 34(31):3607-12. PubMed ID: 27206386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
    Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
    PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.
    Cheeseman HM; Day S; McFarlane LR; Fleck S; Miller A; Cole T; Sousa-Santos N; Cope A; Cizmeci D; Tolazzi M; Hwekwete E; Hannaman D; Kratochvil S; McKay PF; Chung AW; Kent SJ; Cook A; Scarlatti G; Abraham S; Combadiere B; McCormack S; Lewis DJ; Shattock RJ
    Hum Gene Ther; 2018 Sep; 29(9):1011-1028. PubMed ID: 30027768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
    Currier JR; Ngauy V; de Souza MS; Ratto-Kim S; Cox JH; Polonis VR; Earl P; Moss B; Peel S; Slike B; Sriplienchan S; Thongcharoen P; Paris RM; Robb ML; Kim J; Michael NL; Marovich MA
    PLoS One; 2010 Nov; 5(11):e13983. PubMed ID: 21085591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.
    Jacobson JM; Zheng L; Wilson CC; Tebas P; Matining RM; Egan MA; Eldridge J; Landay AL; Clifford DB; Luetkemeyer AF; Tiu J; Martinez AL; Janik J; Spitz TA; Hural J; McElrath J; Frahm N;
    J Acquir Immune Defic Syndr; 2016 Feb; 71(2):163-71. PubMed ID: 26761518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.
    Hemachandra A; Puls RL; Sirivichayakul S; Kerr S; Thantiworasit P; Ubolyam S; Cooper DA; Emery S; Phanuphak P; Kelleher A; Ruxrungtham K
    Hum Vaccin; 2010 Oct; 6(10):835-40. PubMed ID: 20864808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust antibody and cellular responses induced by DNA-only vaccination for HIV.
    De Rosa SC; Edupuganti S; Huang Y; Han X; Elizaga M; Swann E; Polakowski L; Kalams SA; Keefer MC; Maenza J; Lu Y; Wise MC; Yan J; Morrow MP; Khan AS; Boyer JD; Humeau L; White S; Pensiero M; Sardesai NY; Bagarazzi ML; Weiner DB; Ferrari G; Tomaras GD; Montefiori DC; Corey L; McElrath MJ;
    JCI Insight; 2020 Jul; 5(13):. PubMed ID: 32437332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
    Barouch DH; Tomaka FL; Wegmann F; Stieh DJ; Alter G; Robb ML; Michael NL; Peter L; Nkolola JP; Borducchi EN; Chandrashekar A; Jetton D; Stephenson KE; Li W; Korber B; Tomaras GD; Montefiori DC; Gray G; Frahm N; McElrath MJ; Baden L; Johnson J; Hutter J; Swann E; Karita E; Kibuuka H; Mpendo J; Garrett N; Mngadi K; Chinyenze K; Priddy F; Lazarus E; Laher F; Nitayapan S; Pitisuttithum P; Bart S; Campbell T; Feldman R; Lucksinger G; Borremans C; Callewaert K; Roten R; Sadoff J; Scheppler L; Weijtens M; Feddes-de Boer K; van Manen D; Vreugdenhil J; Zahn R; Lavreys L; Nijs S; Tolboom J; Hendriks J; Euler Z; Pau MG; Schuitemaker H
    Lancet; 2018 Jul; 392(10143):232-243. PubMed ID: 30047376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers.
    Kopycinski J; Cheeseman H; Ashraf A; Gill D; Hayes P; Hannaman D; Gilmour J; Cox JH; Vasan S
    Clin Vaccine Immunol; 2012 Sep; 19(9):1557-9. PubMed ID: 22837097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acceptability and tolerability of repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine among healthy African participants in a phase 1 randomized controlled trial.
    Mpendo J; Mutua G; Nanvubya A; Anzala O; Nyombayire J; Karita E; Dally L; Hannaman D; Price M; Fast PE; Priddy F; Gelderblom HC; Hills NK
    PLoS One; 2020; 15(5):e0233151. PubMed ID: 32469893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.
    Mehendale S; van Lunzen J; Clumeck N; Rockstroh J; Vets E; Johnson PR; Anklesaria P; Barin B; Boaz M; Kochhar S; Lehrman J; Schmidt C; Peeters M; Schwarze-Zander C; Kabamba K; Glaunsinger T; Sahay S; Thakar M; Paranjape R; Gilmour J; Excler JL; Fast P; Heald AE
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):873-80. PubMed ID: 18544020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
    Huang X; Zhu Q; Huang X; Yang L; Song Y; Zhu P; Zhou P
    Vaccine; 2017 Apr; 35(16):2042-2051. PubMed ID: 28318765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
    Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
    Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.
    Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandström E
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):193-205. PubMed ID: 28969431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.